

UPVG0003-103
PATENT APPLICATION

SERIAL NO.: 09/935,100
FILED: AUGUST 22, 2001

In the Claims

Please amend claim 32 as follows:

Please add new claims 35-46.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-31 (Canceled)

32. **(Currently amended)** A pharmaceutical composition comprising
- a) anti-Vpr monoclonal antibodies; and
 - b) a pharmaceutically acceptable carrier.
33. **(Previously presented)** A method of treating an individual exposed to HIV by administering an effective amount of anti-Vpr antibodies.
34. **(Previously presented)** A method of treating an individual who has been infected with HIV comprising the step of administering to said individual a therapeutically effective amount of anti-Vpr antibodies.
35. **(New)** The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies are human monoclonal antibodies.
36. **(New)** The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.
37. **(New)** A pharmaceutical composition comprising:
- a) anti-Vpr antibodies that inhibit Vpr enhancement of HIV replication; and
 - b) a pharmaceutically acceptable carrier;

**UPVG0003-103
PATENT APPLICATION**

**SERIAL NO.: 09/935,100
FILED: AUGUST 22, 2001**

wherein the anti-Vpr antibodies are present in an amount effective to inhibit HIV replication in an HIV infected individual.

38. (New) The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are monoclonal antibodies.

39. (New) The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are human monoclonal antibodies.

40. (New) The pharmaceutical composition of claim 37 wherein the composition is a sterile composition and the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

41. (New) The method of claim 33 wherein the anti-Vpr antibodies are monoclonal antibodies.

42. (New) The method of claim 33 wherein the anti-Vpr antibodies are human monoclonal antibodies.

43. (New) The method of claim 33 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

44. (New) The method of claim 34 wherein the anti-Vpr antibodies are monoclonal antibodies.

45. (New) The method of claim 34 wherein the anti-Vpr antibodies are human monoclonal antibodies.

46. (New) The method of claim 34 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.